Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Expectations By $0.16 EPS

Royalty Pharma (NASDAQ:RPRX) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16, Zacks reports. Royalty Pharma had a return on equity of 24.65% and a net margin of 50.53%.

Royalty Pharma Trading Down 0.0 %

Shares of NASDAQ:RPRX opened at $31.72 on Tuesday. Royalty Pharma has a 12-month low of $24.05 and a 12-month high of $32.21. The business’s fifty day simple moving average is $27.93 and its 200-day simple moving average is $27.65. The company has a market capitalization of $18.69 billion, a PE ratio of 16.44 and a beta of 0.49. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be issued a $0.22 dividend. The ex-dividend date is Friday, February 21st. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.77%. Royalty Pharma’s dividend payout ratio (DPR) is currently 43.52%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on RPRX shares. Citigroup decreased their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. Finally, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.